NeuClone’s Trastuzumab Trial Succeeds
Reports Successful Phase I Trial For NeuCeptin Trastuzumab Biosimilar
NeuClone has reported that its NeuCeptin proposed biosimilar trastuzumab has successfully met all primary and secondary endpoints in a Phase I clinical trial.
